Chimerix Stock Price - CMRX

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Chimerix Inc CMRX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.08 -4.02% 1.91 2.00 1.86 1.98 1.99 20:00:00
Bid Price Ask Price Spread Spread % News
1.81 2.09 0.28 13.4% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,821 269,207 $ 1.91 $ 515,403 439,833 1.25 - 4.40
Last Trade Time Type Quantity Stock Price Currency
16:00:53 priorref 100 $ 1.91 USD

Chimerix Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 117.24M 61.38M $ -69.47M -1.43 - 59.93M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Chimerix News

Loading Messages....

Latest CMRX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CMRX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.082.191.862.03246,590-0.17-8.17%
1 Month2.082.441.862.12328,719-0.17-8.17%
3 Months1.452.861.442.05581,2620.4631.72%
6 Months3.534.09991.252.01603,940-1.62-45.89%
1 Year2.424.401.252.30522,807-0.51-21.07%
3 Years5.526.63991.253.44328,522-3.61-65.4%
5 Years37.9558.071.259.48573,436-36.04-94.97%

Chimerix Description

Chimerix Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, oral antivirals in areas of unmet medical needs. The company's focus is on novel nucleosides with activity against influenza, norovirus, CMV, and BK virus, among others. It derives its revenue from two sources contracts and grants, and collaborations and licensing. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of DNA viruses, including smallpox, adenoviruses, and the human herpesviruses. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are currently available.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.